EGFR and non-small cell lung carcinoma: The phase III, randomized ADAURA trial assessed the efficacy and safety of osimertinib as supplementary treatment compared with placebo in patients with completely resected stage IB to IIIA NSCLC with EGFR mutant, after adjuvant chemotherapy, according to physician and patient choices.